Breast Cancer I 14 Treatment For Breast Cancer


Adjuvant therapy in lobar carcinoma in situ

In case of lobar carcinoma in situ, there is no therapeutic benefit after performing an axillary dissection, chemotherapy, or radiotherapy. However, studies have found that there is a 55% reduction in risk when patients use tamoxifen. Thus, patients with lobar carcinoma in situ are sometimes treated with tamoxifen and might need mastectomy in some cases, depending on the size of the tumor.